Despite $30-40 billion in enterprise investment into GenAI so far, “95% of organizations are seeing zero return.” Boards want ...
The expansion of whole-genome sequencing into clinical care has intensified discussions about the limitations of the technology. Illumina ($ILMN) CEO Jay Flatley this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results